Arbutus falls as patent dispute with Moderna hits EU snag
Source: SeekingAlpha
2026-01-16 08:41:17 ET
More on Arbutus Biopharma, Moderna
- Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story
- 44th Annual J.P. Morgan Healthcare Conference
- Moderna, Inc. (MRNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- HHS secretary RFK Jr. adds two new members to CDC vaccine panel
- Moderna reiterates target of up to 10% revenue growth in 2026
Read the full article on Seeking Alpha
For further details see:
Arbutus falls as patent dispute with Moderna hits EU snag
Arbutus Biopharma Corporation
NASDAQ: ABUS
ABUS Trading
1.52% G/L:
$4.685 Last:
774,244 Volume:
$4.67 Open:
ABUS Latest News
November 13, 2025 07:30:00 am
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 07, 2025 08:00:00 am
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
August 06, 2025 07:30:00 am
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
ABUS Stock Data
$811,607,352
153,282,242
0.14%
53
N/A
Biotechnology & Life Sciences
Healthcare
US
Warminster
